FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Expires: December 31, 2014
Estimated average burden
hours per response: 0.5
  
 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person *
Hawkins Richard J
(Last) (First) (Middle)
SCICLONE PHARMACEUTICALS, INC.
950 TOWER LANE, SUITE 900
(Street)
FOSTER CITY CA 94404
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
SCICLONE PHARMACEUTICALS INC [ SCLN ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
09/29/2014
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 09/29/2014   M   50,000 A $ 4.55 50,000 D  
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Non-Qualified Stock Option (right to buy) (1) $ 4.55 09/29/2014   M     50,000   (2) 10/29/2014 Common Stock 50,000 $ 0 0 D  
Explanation of Responses:
1. Granted under the Issuer's 2004 Outside Directors Stock Option Plan.
2. Shares will become exercisable in three equal annual installments beginning on the first anniversary of the date of grant, subject to the Outside Director's continuous service on Issuer's Board of Directors.
/s/Friedhelm Blobel, Attorney-in-Fact for: Richard J. Hawkins 10/01/2014
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
(null) 
LIMITED POWER OF ATTORNEY
FOR SECTION 16(a) REPORTING

	KNOW ALL PERSONS BY THESE PRESENTS, that the undersigned hereby makes,
constitutes and appoints Friedhelm Blobel, Ph.D. and Wilson W. Cheung, and each
of them, as the undersigneds true and lawful attorney-in-fact (the Attorney-in
Fact), with full power of substitution and resubstitution, each with the power
to act alone for the undersigned and in the undersigneds name, place and stead,
in any and all capacities to:

    1.  prepare, execute, deliver and file with the United States Securities and
Exchange Commission, any national securities exchange and SciClone
Pharmaceuticals, Inc. (the Company) any and all reports (including any amendment
thereto) of the undersigned required or considered advisable under Section 16(a)
of the Securities Exchange Act of 1934, as amended (the Exchange Act), and the
rules and regulations thereunder, with respect to the equity securities of the
Company, including Form 3 (Initial Statement of Beneficial Ownership of
Securities), Form 4 (Statement of Changes in Beneficial Ownership), and Form 5
(Annual Statement of Changes in Beneficial Ownership); and

    2.  seek or obtain, as the undersigneds representative and on the
undersigneds behalf, information on transactions in the Companys equity
securities from any third party, including the Company, brokers, dealers,
employee benefit plan administrators and trustees, and the undersigned hereby
authorizes any such third party to release any such information to the Attorney 
in Fact.

    The undersigned acknowledges that:

    1.  this Limited Power of Attorney authorizes, but does not require, the
Attorney-in-Fact to act at his or her discretion on information provided to such
Attorney-in-Fact without independent verification of such information;

    2.  any documents prepared and/or executed by the Attorney-in-Fact on behalf
of the undersigned pursuant to this Limited Power of Attorney will be in such
form and will contain such information as the Attorney-in-Fact, in his or her
discretion, deems necessary or desirable;

    3.  neither the Company nor the Attorney-in-Fact assumes any liability for
the undersigneds responsibility to comply with the requirements of Section 16 of
the Exchange Act, any liability of the undersigned for any failure to comply
with such requirements, or any liability of the undersigned for disgorgement of
profits under Section 16(b) of the Exchange Act; and

    4.  this Limited Power of Attorney does not relieve the undersigned from
responsibility for compliance with the undersigneds obligations under Section 16
of the Exchange Act, including, without, limitation, the reporting requirements
under Section 16(a) of the Exchange Act.

    The undersigned hereby grants to the Attorney-in-Fact full power and
authority to do and perform each and every act and thing requisite, necessary or
convenient to be done in connection with the foregoing, as fully, to all intents
and purposes, as the undersigned might or could do in person, hereby ratifying
and confirming all that the Attorney-in-Fact, or his or her substitute or
substitutes, shall lawfully do or cause to be done by authority of this Limited
Power of Attorney.

    This Limited Power of Attorney shall remain in full force and effect until
the undersigned is no longer required to file Forms 3, 4 or 5 with respect to
the undersigneds holdings of and transactions in equity securities of the
Company, unless earlier revoked by the undersigned in a signed writing delivered
to the Attorney-in-Fact.

    This Limited Power of Attorney shall be governed and construed in accordance
the laws of the State of California without regard to the laws that might
otherwise govern under applicable principles of conflicts of laws thereof.

    IN WITNESS WHEREOF, the undersigned has caused this Limited Power of
Attorney to be executed as of August 1, 2013.

Signature:      /s/ Richard J. Hawkins

Print Name:        Richard J. Hawkins